US Veterinary Development Programme for CannEpil Commences
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The program will focus on companion-animal oncology and chronic pain management, establishing a regulatory pathway through the U.S. FDA. Dr. Hunter Land, with extensive experience in cannabinoid pharmaceuticals, will lead the development team. This milestone follows Argent's expansion of CannEpil into veterinary healthcare, retaining ownership of its intellectual property and regulatory assets.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Argent Biopharma
- CannEpil Global Licence Expands into Veterinary Healthcare
- RGT Executes Global CannEpil Licensing Deal for US$5.5M
- Half Yearly Report and Accounts
- Provisional Patent Lodged with USPTO for NanoBodies Platform
- CannEpil - Largest Commercial Shipment Arrives in Ireland
Later from Argent Biopharma
- FDA-CVM Establish INAD File for CannEpil Veterinary Program
- Appendix 4E and 2026 Annual Report
- Argent Signs NLC Licence to Expand Antiviral Portfolio
- Execution of Loan Facility Agreement
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma